zoledronic acid

zoledronate

A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1699" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1699" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000042507

zoledronate

ZOL 446

Zometa

CGP42446A

NDC-zoledronate

CGP 42446

[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid

118072-93-8

http://purl.bioontology.org/ontology/PDQ/CDR0000256190

http://purl.bioontology.org/ontology/PDQ/CDR0000362077

http://purl.bioontology.org/ontology/PDQ/CDR0000352014

http://purl.bioontology.org/ontology/PDQ/CDR0000393518

http://purl.bioontology.org/ontology/PDQ/CDR0000362078

http://purl.bioontology.org/ontology/PDQ/CDR0000386169

http://purl.bioontology.org/ontology/PDQ/CDR0000415928

http://purl.bioontology.org/ontology/PDQ/CDR0000038395

http://purl.bioontology.org/ontology/PDQ/CDR0000362076

http://purl.bioontology.org/ontology/PDQ/CDR0000362084

http://purl.bioontology.org/ontology/PDQ/CDR0000362079

http://purl.bioontology.org/ontology/PDQ/CDR0000038394

http://purl.bioontology.org/ontology/PDQ/CDR0000258367

http://purl.bioontology.org/ontology/PDQ/CDR0000377523

http://purl.bioontology.org/ontology/PDQ/CDR0000362075

http://purl.bioontology.org/ontology/PDQ/CDR0000038393

http://purl.bioontology.org/ontology/PDQ/CDR0000038663

C0528130

C0257685

C1521936

C0392938

C0939788

2008-02-26

A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1699" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1699" NCI Thesaurus)

6117

TRD

C1699

CDR0000042507

721517

Drug/agent

zoledronic acid

T109

T121